CASI Pharmaceuticals, Inc. (CASIF)

CASI Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	3.77	5.63	13.47	17.08	47.11	38.7
Short-Term Investments	-	-	2.62	13.69	4.23	9.87
Cash & Short-Term Investments	3.77	5.63	16.09	30.77	51.34	48.57
Cash Growth	-44.32%	-65.00%	-47.70%	-40.06%	5.69%	-26.82%
Accounts Receivable	3.44	4.09	15.35	9.55	12.97	9.8
Other Receivables	-	-	-	0.59	-	-
Receivables	3.44	4.09	15.35	10.14	12.97	9.8
Inventory	1.84	1.6	5.25	15.88	6.14	1.91
Prepaid Expenses	0.98	2.14	2.89	2.56	2.98	1.69
Total Current Assets	10.02	13.46	39.58	59.34	73.42	61.97
Property, Plant & Equipment	8.43	9.52	11.36	11.63	13.23	21.82
Long-Term Investments	1.72	1.72	1.91	1.69	7.46	40.13
Other Intangible Assets	0.21	0.22	0.24	1.84	1.06	12.2
Other Long-Term Assets	0.68	0.74	0.59	0.77	1.06	2.18
Total Assets	21.06	25.65	53.67	75.27	96.23	138.3

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	1.07	1.07	2.72	4.44	3.29	2.22
Accrued Expenses	25.06	13.9	8.47	7.15	7.64	6.04
Short-Term Debt	1.47	1	-	-	-	-
Current Portion of Long-Term Debt	39.02	23.43	18.39	-	-	-
Current Portion of Leases	-	1.61	1.22	0.73	0.87	1.06
Current Income Taxes Payable	-	-	-	-	1.9	-
Current Unearned Revenue	-	2.58	2.47	2.54	2.62	0.06
Other Current Liabilities	-	6.08	3.18	1.87	0.69	3.81
Total Current Liabilities	66.62	49.67	36.45	16.73	17.01	13.19
Long-Term Debt	-	-	-	18.9	-	-
Long-Term Leases	-	1.44	2.54	1.62	0.48	1.11
Long-Term Unearned Revenue	-	-	-	-	-	2.83
Other Long-Term Liabilities	12.71	11.82	12.84	13.87	11.82	13.22
Total Liabilities	79.33	62.93	51.82	51.1	29.3	30.34

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0	0	0	0	0	0
Additional Paid-In Capital	722.31	722.24	713.3	695.79	691.77	696.22
Retained Earnings	-768.17	-748.13	-700.08	-660.82	-637.16	-605.64
Treasury Stock	-9.6	-9.6	-9.6	-9.6	-9.33	-8.03
Comprehensive Income & Other	-2.8	-1.79	-1.77	-1.2	-0.7	1.95
Total Common Equity	-58.27	-37.28	1.85	24.17	44.57	84.5
Minority Interest	-	-	-	-	22.36	23.46
Shareholders' Equity	-58.27	-37.28	1.85	24.17	66.93	107.96
Total Liabilities & Equity	21.06	25.65	53.67	75.27	96.23	138.3

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	40.5	27.49	22.14	21.24	1.34	2.17
Net Cash (Debt)	-36.73	-21.85	-6.05	9.53	49.99	46.41
Net Cash Growth	-	-	-	-80.94%	7.73%	-26.55%
Net Cash Per Share	-1.74	-1.18	-0.39	0.71	3.66	3.41
Filing Date Shares Outstanding	20.56	20.56	15.49	12.99	13.32	13.66
Total Common Shares Outstanding	20.56	20.56	15.49	13.38	13.46	13.98
Working Capital	-56.59	-36.21	3.12	42.62	56.42	48.78
Book Value Per Share	-2.83	-1.81	0.12	1.81	3.31	6.04
Tangible Book Value	-58.48	-37.5	1.61	22.33	43.51	72.3
Tangible Book Value Per Share	-2.84	-1.82	0.10	1.67	3.23	5.17
Machinery	-	6.77	6.58	6.68	1.24	1.73
Construction In Progress	-	-	-	0.02	5.73	12.1
Leasehold Improvements	-	7.29	7	7.19	7.16	1.13

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 31, 2026

Data Sources Report a data error